関連する実験動画

Updated: Feb 21, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

IRF2BP2::JAK2は,小児T細胞急性リンパ性白血病における新しいキナーゼ活性化融合を定義しています

Fatimah B Jalud¹, Tasnia Ibnat², Kaitlyn Kew^1,3

¹Olivia Newton-John Cancer Research Institute, Heidelberg, Melbourne, Australia.

Genes, chromosomes & cancer

|February 19, 2026

まとめ

研究者らは,小児のT細胞急性リンパ性白血病 (T-ALL) で新しいIRF2BP2::JAK2融合を特定しました. この融合は癌の成長を促し,JAK阻害剤によって標的となり,高リスクのT-ALL患者にとって新しい治療戦略を提供します.

科学分野:

腫瘍学腫瘍学
遺伝学遺伝学とは
分子生物学は分子生物学である.

背景:

T細胞急性リンパ性白血病 (T-ALL) は,再発または耐性症例の悪質なアウトカムを持つ攻撃的な癌です.
T-ALLにおけるチロシンキナーゼの変化を理解することは,標的治療の開発に不可欠です.

研究の目的:

高リスクの小児性T-ALL.における新たな腫瘍原発の要因を特定し,特徴づけること.
IRF2BP2::JAK2 融合の機能的および治療的関連性を調査する.

主な方法:

遺伝子変化を特定するために全ゲノムとトランスクリプトームの配列決定.
CRISPR-Cas9ゲノムエンジニアリングにより,細胞系におけるIRF2BP2::JAK2融合をモデル化しました.
細胞成長とシグナル伝達経路を評価するための機能検査.
JAK阻害剤 (ルクソリチニブ,CHZ868) の有効性を試験する.

主要な成果:

IRF2BP2::JAK2融合の最初の症例は,小児のT-ALL患者で確認されました.
融合により,サイトカインに依存しない成長と構成的なJAK-STATシグナル伝達が生じる.
I型およびII型JAK阻害剤の両方が,融合タンパク質を効果的に阻害しました.

結論:

IRF2BP2::JAK2は,新しい腫瘍原発であり,T-ALL.の薬効性の脆弱性である.
この融合は,IRF2BP2が非受容体であるチロシンキナーゼを活性化する最初の報告例を表しています.
機能モデリングは,T-ALLの精密医学に希少なゲノム発見を翻訳するために不可欠です.

さらに関連する動画

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

関連する概念動画

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

Receptor Tyrosine Kinases

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...